Accession Number: | 0001127602-21-012256 |
Date: | 2021-03-26 |
Issuer: | CVS HEALTH CORP (CVS) |
Original Submission Date: |
MERLO LARRY J
ONE CVS DRIVE
WOONSOCKET, RI 02895-
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
COMMON STOCK | 2021-03-26 | M | 271,347 | a | $74.29 | 794,676 | direct | ||
COMMON STOCK | 2021-03-26 | S | 270,650 | d | $74.73 | 524,026 | direct | ||
COMMON STOCK | 2021-03-26 | 0 | $0.00 | 406,634 | indirect | ||||
COMMON STOCK (RESTRICTED) | 2021-03-26 | 0 | $0.00 | 40,701 | direct | ||||
ESOP COMMON STOCK | 2021-03-26 | 0 | $0.00 | 7,548 | indirect | ||||
STOCK UNIT | 2021-03-26 | 0 | $0.00 | 688,686 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
STOCK OPTION | 74.29 | 2021-03-26 | deemed execution date | M | 271,347 (d) | 2015-04-01 | 2021-04-01 | common stock 271,347 | $74.29 | 0 | direct | |
PHANTOM STOCK CREDITS | 1.0 | 2021-03-26 | deemed execution date | 0 ( ) | common stock 5,153 | $1.00 | 5,153 | direct | ||||
STOCK OPTION | 102.26 | 2021-03-26 | deemed execution date | 0 ( ) | 2016-04-01 | 2022-04-01 | common stock 273,929 | $102.26 | 273,929 | direct | ||
STOCK OPTION | 104.82 | 2021-03-26 | deemed execution date | 0 ( ) | 2017-04-01 | 2023-04-01 | common stock 286,787 | $104.82 | 286,787 | direct | ||
STOCK OPTION | 78.05 | 2021-03-26 | deemed execution date | 0 ( ) | 2018-04-03 | 2024-04-03 | common stock 338,105 | $78.05 | 338,105 | direct | ||
STOCK OPTION | 62.21 | 2021-03-26 | deemed execution date | 0 ( ) | 2019-04-01 | 2025-04-01 | common stock 394,091 | $62.21 | 394,091 | direct | ||
STOCK OPTION | 54.19 | 2021-03-26 | deemed execution date | 0 ( ) | 2020-04-01 | 2029-04-01 | common stock 545,419 | $54.19 | 545,419 | direct | ||
STOCK OPTION | 58.34 | 2021-03-26 | deemed execution date | 0 ( ) | 2021-04-01 | 2030-04-01 | common stock 478,711 | $58.34 | 478,711 | direct |
ID | footnote |
---|---|
f1 | all sales were effected pursuant to a rule 10b5-1 plan. the transaction was a sell-to-cover exercise, with shares sold to cover the option exercise price and taxes, and the reporting person retaining all remaining shares. |
f2 | represents weighted average sale prices for this group of sales, which occurred on the same trading day. multiple sales were executed, with sales prices ranging between $74.49 and $75.73 per share. |
f3 | option became exercisable in four equal annual installments, commencing 4/1/2015. |
f4 | each share credit is equivalent to one share; 1-for-1 conversion. |
f5 | reflects year end company match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person. |
f6 | reflects year end company match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person. |
f7 | option became exercisable in four equal annual installments, commencing 4/1/2016. |
f8 | option became exercisable in four equal annual installments, commencing 4/1/2017. |
f9 | option became exercisable in four equal annual installments, commencing 4/3/2018. |
f10 | option became exercisable in four equal annual installments, commencing 4/1/2019. |
f11 | option became exercisable in four equal annual installments, commencing 4/1/2020. |
f12 | the number of shares subject to the option were calculated using a 30-day average price. |
f13 | option becomes exercisable in four equal annual installments, commencing 4/1/2021. |